Clinical trials
Moderate to Severe Plaque Psoriasis clinical trials
Below are recruiting moderate to severe plaque psoriasis clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06696417Recruiting
Testing vunakizumab for moderate to severe plaque psoriasis
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
Shenyang, LiaoningAges 18 years+ - NCT07039110Recruiting
Risankizumab for psoriasis: quality of life study
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
Calgary, AlbertaAges 18 years+ - NCT07038720RecruitingPhase 1
Testing an experimental oral tablet for moderate to severe psoriasis
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
Hangzhou, ZhejiangAges 18–55 - NCT06999941Enrolling by invitation
Study of deucravacitinib for psoriasis with eczema features
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06979453RecruitingPhase 3
A study of deucravacitinib for teens with plaque psoriasis
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Birmingham, AlabamaAges 12–17 - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+ - NCT06842199RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
Hefei, AnhuiAges 18–75 - NCT04772079RecruitingPhase 3
Test drug safety and effectiveness for youth plaque psoriasis
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
Ciudad Autonoma de Buenos Aires, Buenos AiresAges 4–18 - NCT07746583Recruiting
Switching from ustekinumab to guselkumab for psoriasis
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
BudapestAges 18 years+ - NCT06987292Recruiting
Studying IL-17 inhibitors for hidden tendon inflammation in psoriasis
This study tests whether IL-17 inhibitor medications can reduce inflammation in tendons and ligaments that is not visible on the skin but can be detected with a special ultrasound. It may be an option for people with moderate to severe psoriasis who have not had enough relief from creams or light therapy.
Nanjing, JiangsuAges 18 years+ - NCT07663331RecruitingPhase 4
Adalimumab for adults with non-infectious uveitis
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06857942RecruitingPhase 4
Tirzepatide added to ixekizumab for psoriasis and weight issues
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
Phoenix, ArizonaAges 18 years+ - NCT04347473RecruitingPhase 4
ILUMYA plus halobetasol ointment for plaque psoriasis
This trial studies whether ILUMYA (an injection) working together with halobetasol ointment helps control moderate-to-severe plaque psoriasis. It is meant for adults whose psoriasis is significant enough that they may need light therapy (phototherapy) and/or pills/injections (systemic therapy).
East Windsor, New JerseyAges 18 years+ - NCT07243782Recruiting
Study of Cosentyx for skin and joint conditions in Korea
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Seoul, SeoulAges 6–100 - NCT07116967RecruitingPhase 3
Long-term safety of two psoriasis drugs in people with heart risk
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
Birmingham, AlabamaAges 40 years+ - NCT05644782Recruiting
Diet study for mild-to-moderate psoriasis in adults
This trial studies whether a dietary approach can help people with mild-to-moderate psoriasis. It may be especially focused on people who do not have signs of wheat/gluten-related immune reactions.
Palermo, PalermoAges 18–65 - NCT06701513Recruiting
Real-world study of deucravacitinib for plaque psoriasis
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
AmiensAges 18 years+ - NCT06382051Recruiting
Improving Psoriatic Arthritis Screening in Psoriasis
This study tests a new way to screen for psoriatic arthritis (a type of joint inflammation) in people with psoriasis. It looks at a tool called PEST and aims to improve early detection.
Calgary, AlbertaAges 18 years+
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderate to severe plaque psoriasis?
- Yes. Clin2 currently lists 42 recruiting moderate to severe plaque psoriasis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderate to severe plaque psoriasis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderate to severe plaque psoriasis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.